Brokerages expect TRACON Pharmaceuticals Inc (NASDAQ:TCON) to report ($1.57) earnings per share (EPS) for the current quarter, Zacks Investment Research reports. Zero analysts have provided estimates for TRACON Pharmaceuticals’ earnings. The lowest EPS estimate is ($1.64) and the highest is ($1.50). TRACON Pharmaceuticals posted earnings of ($2.60) per share during the same quarter last year, which indicates a positive year over year growth rate of 39.6%. The firm is scheduled to report its next earnings report on Thursday, February 27th.
On average, analysts expect that TRACON Pharmaceuticals will report full-year earnings of ($7.75) per share for the current fiscal year, with EPS estimates ranging from ($7.89) to ($7.60). For the next year, analysts anticipate that the company will report earnings of ($1.24) per share, with EPS estimates ranging from ($4.48) to $2.00. Zacks Investment Research’s earnings per share averages are a mean average based on a survey of research analysts that follow TRACON Pharmaceuticals.
TRACON Pharmaceuticals (NASDAQ:TCON) last issued its quarterly earnings data on Tuesday, November 5th. The biopharmaceutical company reported ($0.17) earnings per share for the quarter, topping the consensus estimate of ($0.20) by $0.03.
TCON traded up $0.02 during midday trading on Friday, hitting $3.07. The stock had a trading volume of 18,664 shares, compared to its average volume of 30,458. The company has a market cap of $9.64 million, a P/E ratio of -0.24 and a beta of 2.24. The business has a fifty day moving average of $2.07 and a 200 day moving average of $0.93. The company has a debt-to-equity ratio of 0.84, a quick ratio of 1.58 and a current ratio of 1.58. TRACON Pharmaceuticals has a 1 year low of $2.78 and a 1 year high of $17.30.
Hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. Susquehanna International Group LLP acquired a new stake in shares of TRACON Pharmaceuticals during the 2nd quarter worth about $26,000. Wedbush Securities Inc. purchased a new stake in shares of TRACON Pharmaceuticals during the 2nd quarter worth approximately $32,000. Finally, Renaissance Technologies LLC boosted its stake in shares of TRACON Pharmaceuticals by 17.5% during the 2nd quarter. Renaissance Technologies LLC now owns 1,209,203 shares of the biopharmaceutical company’s stock worth $822,000 after acquiring an additional 179,718 shares in the last quarter.
About TRACON Pharmaceuticals
TRACON Pharmaceuticals, Inc, a biopharmaceutical company, focuses on the development and commercialization of therapeutics for cancer and wet age-related macular degeneration (AMD). Its lead product candidate is TRC105, an endoglin antibody, which is in randomized Phase III clinical trial for angiosarcoma; Phase I/II clinical trial for hepatocellular carcinoma; Phase I clinical trial for lung cancer; Phase I/II clinical trial for breast cancer; Phase II clinical trials for prostate cancer; and randomized Phase II clinical trial for wet AMD.
Featured Story: How can investors find ex-dividend dates?
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for TRACON Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for TRACON Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.